Chelsea Completes Successful NORTHERA Pre-NDA Assessment With FDA

Chelsea completes successful NORTHERA pre-NDA assessment with FDA
Chelsea Therapeutics International, Ltd. announced it has completed a pre-NDA assessment with the U.S. Food and Drug Administration (FDA) and intends to accelerate its new drug application (NDA) for NORTHERA™(droxidopa) for the treatment of symptomatic, neurogenic orthostatic hypotension (NOH), a chronic and potentially debilitating drop in blood pressure upon standing commonly associated …
Read more on News-Medical-Net

Lightlake acquires US Patent for method of terminating methadone maintenance
Lightlake Therapeutics Inc has acquired US Patent 5,587,381, entitled: ‘Method for terminating methadone maintenance through extinction of the opiate-taking responses’, using an opioid antagonist as treatment. The Patent also covers treatment for addiction to other legally available opioids and to stimulant drugs such as Cocaine and Amphetamines.
Read more on News-Medical-Net

Four men deny drug offences at Carlisle court hearing
Four men denied a string of drugs offences when they appeared at Carlisle Crown Court.
Read more on The News and Star